Profile data is unavailable for this security.
About the company
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Company’s segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.
- Revenue in INR (TTM)25.80bn
- Net income in INR-1.54bn
- Incorporated2007
- Employees1.30k
- LocationDishman Carbogen Amcis LtdDishman Corporate HouseIscon-Bopal Road, AmbliAHMEDABAD 380058IndiaIND
- Phone+91 2 717420100
- Fax+91 7 926420198
- Websitehttps://www.carbogen-amcis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Suven Life Sciences Ltd | 119.19m | -1.06bn | 24.39bn | 132.00 | -- | -- | -- | 204.65 | -5.20 | -5.20 | 0.5759 | -- | -- | -- | -- | 902,939.40 | -- | -31.29 | -- | -35.32 | -- | 66.93 | -890.87 | -127.02 | -- | -744.27 | -- | -- | 14.31 | -53.54 | 3.06 | -- | -41.37 | -- |
| RPG Life Sciences Limited | 5.74bn | 847.70m | 25.15bn | 1.17k | 29.66 | -- | 24.84 | 4.38 | 51.26 | 51.26 | 346.80 | -- | -- | -- | -- | -- | -- | 13.08 | -- | 18.26 | 68.17 | 62.42 | 14.78 | 9.71 | -- | 296.86 | -- | 29.26 | 16.51 | 8.12 | 31.39 | 38.13 | 16.15 | 37.97 |
| Jeena Sikho Lifecare Ltd | -100.00bn | -100.00bn | 25.51bn | 1.23k | -- | 80.69 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| Innova Captab Ltd | -100.00bn | -100.00bn | 27.49bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 15.72 | -- | 6.26 | -- | -- | -- |
| Supriya Lifescience Ltd | 5.54bn | 1.20bn | 29.58bn | 392.00 | 24.55 | -- | 21.86 | 5.34 | 14.97 | 14.97 | 68.93 | -- | -- | -- | -- | 14,144,410.00 | -- | 20.77 | -- | 29.06 | 61.94 | 55.83 | 21.72 | 24.33 | -- | 63.63 | -- | 2.02 | -13.04 | 16.70 | -40.81 | 59.41 | 85.55 | -- |
| SeQuent Scientific Ltd | 13.75bn | -1.29bn | 30.53bn | 478.00 | -- | -- | -- | 2.22 | -5.18 | -5.18 | 55.33 | -- | -- | -- | -- | 28,769,920.00 | -- | 2.33 | -- | 3.67 | 42.78 | 42.47 | -8.97 | 2.59 | -- | -0.3894 | -- | 17.27 | 0.5728 | 10.84 | -395.83 | -- | 12.88 | -- |
| Indoco Remedies Ltd | 17.96bn | 1.02bn | 30.67bn | 6.10k | 30.45 | -- | 16.66 | 1.71 | 10.93 | 10.93 | 192.26 | -- | -- | -- | -- | 2,943,454.00 | -- | 6.07 | -- | 8.90 | 69.39 | 65.35 | 5.61 | 6.30 | -- | 5.11 | -- | 14.79 | 8.30 | 9.81 | -8.11 | 28.15 | 8.25 | 17.61 |
| Gufic BioSciences Ltd | 7.85bn | 841.95m | 31.00bn | 1.63k | 35.85 | -- | 29.39 | 3.95 | 8.62 | 8.62 | 80.38 | -- | -- | -- | -- | 4,820,074.00 | -- | 12.30 | -- | 23.08 | 51.08 | 44.91 | 10.73 | 9.84 | -- | 8.22 | -- | 1.39 | -11.36 | 17.47 | -16.84 | 37.06 | 86.82 | 14.87 |
| Dishman Carbogen Amcis Ltd | 25.80bn | -1.54bn | 35.67bn | 1.30k | -- | -- | 24.21 | 1.38 | -9.84 | -9.84 | 164.35 | -- | -- | -- | -- | 19,919,850.00 | -- | 0.4699 | -- | 0.5665 | 76.93 | 74.36 | -5.98 | 1.82 | -- | -0.1245 | -- | 202.76 | 12.72 | 7.32 | -265.46 | -- | 21.54 | -- |
| Hikal Ltd | 18.16bn | 716.22m | 37.10bn | 2.14k | 51.84 | -- | 20.19 | 2.04 | 5.80 | 5.80 | 147.17 | -- | -- | -- | -- | 8,477,077.00 | -- | 5.86 | -- | 8.87 | 52.08 | 45.41 | 3.94 | 6.37 | -- | 2.78 | -- | 10.14 | 4.13 | 9.25 | -51.16 | 0.2973 | 23.35 | 4.42 |
| Unichem Laboratories Ltd | 16.75bn | 145.69m | 39.48bn | 3.12k | 271.39 | -- | 30.29 | 2.36 | 2.07 | 2.07 | 234.69 | -- | -- | -- | -- | 5,364,373.00 | -- | -1.38 | -- | -1.66 | 59.94 | 56.15 | 0.8696 | -3.60 | -- | -0.9613 | -- | -- | 5.76 | 10.51 | -711.67 | -- | -22.60 | -- |
| Advanced Enzyme Technologies Ltd | 6.05bn | 1.37bn | 40.23bn | 338.00 | 29.30 | -- | 23.17 | 6.65 | 12.28 | 12.28 | 54.16 | -- | -- | -- | -- | 17,892,400.00 | -- | 11.87 | -- | 13.19 | 76.42 | 72.20 | 23.02 | 25.79 | -- | 59.04 | -- | 7.49 | 2.13 | 6.44 | -11.66 | 3.24 | 28.32 | 14.87 |
| Aarti Pharmalabs Ltd | 18.32bn | 1.95bn | 42.47bn | 1.40k | 21.83 | -- | 16.05 | 2.32 | 21.47 | 21.47 | 202.17 | -- | -- | -- | -- | 13,085,090.00 | -- | -- | -- | -- | 42.00 | -- | 10.62 | -- | -- | 16.14 | -- | -- | 62.11 | -- | 58.27 | -- | -- | -- |
| Aarti Drugs Ltd | 26.51bn | 1.80bn | 45.48bn | 1.50k | 25.34 | -- | 19.70 | 1.72 | 19.52 | 19.52 | 287.30 | -- | -- | -- | -- | 17,673,360.00 | -- | 9.91 | -- | 16.40 | 32.25 | 22.33 | 6.81 | 8.23 | -- | 8.29 | -- | 5.53 | 9.14 | 16.56 | -18.89 | 15.11 | 17.20 | 31.95 |
Data as of Apr 18 2024. Currency figures normalised to Dishman Carbogen Amcis Ltd's reporting currency: Indian Rupee INR
6.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HBM Partners AG (Investment Management)as of 30 Sep 2023 | 5.56m | 3.55% |
| quant Money Managers Ltd.as of 31 Mar 2024 | 1.82m | 1.16% |
| HSBC Asset Management (India) Pvt Ltd.as of 31 Mar 2024 | 1.48m | 0.94% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 1.21m | 0.77% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 222.48k | 0.14% |
| American Century Investment Management, Inc.as of 04 Apr 2024 | 109.94k | 0.07% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Mar 2024 | 96.99k | 0.06% |
| Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 52.56k | 0.03% |
| DFA Australia Ltd.as of 29 Feb 2024 | 13.16k | 0.01% |
| Groww Asset Management Ltd.as of 31 Mar 2024 | 431.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 11 Apr 2024Source: FactSet Research Systems Inc.
